Catalyst Pharmaceuticals, Inc. CPRX
Set alert
As of Jul 15, 9:30 AM ET
52-week range unavailable
- YTD
- +34.92%
- 1 year
- +43.86%
- Open
- 31.49
- Prev close
- 31.49
- Mkt cap
- 3.85B
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 31.49
- High
- 31.49
- Beta
- 0.74
- Inst. own
- 90.00%
- Dividend
- 0.00
- Earnings
- Aug 5, 2026
1Y chart
Events in this range
- Aug 6, 2025Earnings: 0.43; estimate 0.58; surprise -25.86%
- Nov 5, 2025Earnings: 0.43; estimate 0.51; surprise -15.69%
- Nov 7, 2025Rating: Citigroup · Buy → Buy
- Feb 25, 2026Earnings: 0.42; estimate 0.42; surprise 0%
- Mar 3, 2026Rating: Citigroup · Buy → Buy
- May 7, 2026Downgrade: Stephens & Co. · Overweight → Equal-Weight
- May 8, 2026Downgrade: Citigroup · Buy → Neutral
- May 11, 2026Earnings: 0.52; estimate 0.64; surprise -18.75%
- May 28, 2026Downgrade: HC Wainwright & Co. · Buy → Neutral
Signals (39)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Jul 14, 2026 | 3 months ago |
| RSI: Overbought | Jul 2, 2026 | 4 months ago |
| MACD: Sell Signal | May 19, 2026 | 5 months ago |
| RSI: Overbought | May 5, 2026 | 6 months ago |
| RSI: Overbought | Apr 27, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bullish | Mar 26, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 26, 2026 | 7 months ago |
| SMA: Bearish | Mar 12, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 12, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Feb 27, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 27, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 13, 2026 | 8 months ago |
| SMA: Bearish | Feb 12, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 10, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 21, 2026 | 9 months ago |
| SMA: Bullish | Jan 20, 2026 | 9 months ago |
Newest 20 of 39.
Key statistics
- Market cap
- 3.85B
- Enterprise value
- 3.10B
- Trailing P/E
- 17.49
- PEG ratio
- 2.07
- Price / sales
- 6.46
- Price / book
- 3.80
- Beta
- 0.74
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 37.08%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 23.65%
Analyst view
- Strong buy0
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.73589.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.48 | — | — | — |
| May 11, 2026 | Mar 31, 2026 | 0.64 | 0.52 | -0.12 | -18.75% |
| Feb 25, 2026 | Dec 31, 2025 | 0.42 | 0.42 | 0.00 | 0.00% |
| Nov 5, 2025 | Sep 30, 2025 | 0.51 | 0.43 | -0.08 | -15.69% |
| Aug 6, 2025 | Jun 30, 2025 | 0.58 | 0.43 | -0.15 | -25.86% |
| May 7, 2025 | Mar 31, 2025 | 0.53 | 0.47 | -0.06 | -11.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| May 8, 2026 | Citigroup | down | Buy | Neutral |
| May 7, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Mar 3, 2026 | Citigroup | main | Buy | Buy |
| Nov 7, 2025 | Citigroup | main | Buy | Buy |
| Mar 3, 2025 | Baird | main | Outperform | Outperform |
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 182
- Website
- catalystpharma.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on CPRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DALY RICHARD J | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 4, 2026 | 271,266 |
| DEL CARMEN JEFFREY | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 14,337 |
| DENKHAUS DONALD A | Director | Conversion of Exercise of derivative security | Dec 28, 2025 | 498,773 |
| ELSBERND BRIAN D | Officer | Conversion of Exercise of derivative security | Dec 28, 2025 | 242,501 |
| INGENITO GARY | Officer | Conversion of Exercise of derivative security | May 13, 2025 | 68,873 |
| MCENANY PATRICK JAMES | Chairman of the Board | Conversion of Exercise of derivative security | Dec 28, 2025 | 4,171,560 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 15.34% | 18,774,530 | 591.21M | Mar 30, 2026 |
| State Street Corporation | 5.61% | 6,863,060 | 216.12M | Mar 30, 2026 |
| Vanguard Capital Management LLC | 4.18% | 5,122,666 | 161.31M | Mar 30, 2026 |
| American Century Companies Inc | 3.38% | 4,138,416 | 130.32M | Mar 30, 2026 |
| Deerfield Management Company, L.P | 3.22% | 3,943,600 | 124.18M | Mar 30, 2026 |
| Dimensional Fund Advisors LP | 2.80% | 3,429,615 | 108.00M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.72% | 7,007,375 | 220.66M | May 30, 2026 |
| American Century ETF Trust-Avantis U.S. Small Cap Value ETF | 3.81% | 4,670,219 | 147.07M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.03% | 3,711,365 | 116.87M | Mar 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.43% | 2,974,227 | 93.66M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.25% | 2,759,811 | 86.91M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.05% | 1,287,998 | 40.56M | Mar 30, 2026 |